Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of biochemical markers of bone turnover in metastatic breast cancer patients switched from intravenous zoledronic acid to oral ibandronate
2005-004513-15Phase 3Completed
- Sponsor
- Christoph Zielinski
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibandronate in breast cancer, sponsored by Christoph Zielinski. Primary endpoint: Serum biochemical markers of bone turnover. Started Oct 2005; status: completed.
02
Drugs
ibandronate
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004513-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004513-15.